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Background
Multi-organ disease with cardiac involvement carries a
very poor prognosis in Systemic AL Amyloidosis. The
risk of nephrogenic systemic fibrosis is a significant
obstacle in assessing cardiac status using CMR in
patients with systemic AL amyloidosis who have
advanced renal failure. Measurement of myocardial T1
values has been limited until now, due to long breath-
hold times. We have developed a robust and clinically
applicable technique for diagnosing cardiac amyloidosis
by measuring absolute myocardial T1 values using the
single breath hold, Shortened Modified Look-Locker
Inversion Recovery (ShMOLLI) sequence without gado-
linium administration.
Methods
Thirty-five patients (23 males, 12 females, mean age 60
years) with systemic AL amyloidosis underwent conven-
tional CMR scanning with cine imaging and late gadoli-
nium imaging as well as ShMOLLI pre-contrast T1-
mapping between both centres; all patients had an eGFR
of >30ml/min. Myocardial T1 values from the basal sep-
tum in the apical 4-chamber view were measured and
compared against cardiac biomarkers, and ECG data.
Results were compared to normal controls (n=54). Con-
ventional clinical assessment using the Mayo staging
system ranked cardiac involvement as definite, probable
and none.
Results
Myocardial T1 was significantly higher in all patients
with systemic AL amyloidosis compared to normals
(1057 vs 967, P<0.001). When assessed against pre-test
probability of cardiac involvement based on clinical eva-
luation, myocardial T1 in patients with probable and
definite cardiac disease was significantly higher than
normals (P<0.005) (see figure 1). Myocardial T1 corre-
lated linearly with indexed LV mass (R
2 0.21, P<0.005),
BNP (R
2 0.49, P<0.005) and inversely with ejection frac-
tion (R
2 0.31, P<0.005) and QRS voltage on ECG (R
2
0 . 3 2 ,P < 0 . 0 0 5 )( s e ef i g u r e2 ) .C o r r e l a t i o n sw e r en o t
observed with markers of functional assessment such as
NYHA class and ECOG status, possibly due to con-
founding variables such as co-existing peripheral neuro-
pathy and degree of fluid overload.
Conclusions
Using the ShMOLLI sequence to measure absolute myo-
cardial T1 times in patients with systemic AL
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Figure 1 showing pre-contrast, mean myocardial T1 in patients
with cardiac AL amyloidosis, subgrouped into pre-test clinical
probability of cardiac involvement.
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ing the presence or otherwise of cardiac involvement by
amyloid and it correlates well with currently accepted
measures of cardiac dysfunction in amyloidosis.
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Figure 2 showing the correlation between pre-contrast, mean
myocardial T1 by ShMOLLI and mean indexed LV mass.
Karamitsos et al. Journal of Cardiovascular Magnetic Resonance 2012, 14(Suppl 1):O76
http://www.jcmr-online.com/content/14/S1/O76
Page 2 of 2